1. Home
  2. BDSX vs EDIT Comparison

BDSX vs EDIT Comparison

Compare BDSX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • EDIT
  • Stock Information
  • Founded
  • BDSX 2005
  • EDIT 2013
  • Country
  • BDSX United States
  • EDIT United States
  • Employees
  • BDSX N/A
  • EDIT N/A
  • Industry
  • BDSX Precision Instruments
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BDSX Health Care
  • EDIT Health Care
  • Exchange
  • BDSX Nasdaq
  • EDIT Nasdaq
  • Market Cap
  • BDSX 194.9M
  • EDIT 176.7M
  • IPO Year
  • BDSX 2020
  • EDIT 2016
  • Fundamental
  • Price
  • BDSX $1.51
  • EDIT $1.32
  • Analyst Decision
  • BDSX Strong Buy
  • EDIT Buy
  • Analyst Count
  • BDSX 4
  • EDIT 14
  • Target Price
  • BDSX $3.08
  • EDIT $8.08
  • AVG Volume (30 Days)
  • BDSX 332.5K
  • EDIT 3.3M
  • Earning Date
  • BDSX 11-01-2024
  • EDIT 11-04-2024
  • Dividend Yield
  • BDSX N/A
  • EDIT N/A
  • EPS Growth
  • BDSX N/A
  • EDIT N/A
  • EPS
  • BDSX N/A
  • EDIT N/A
  • Revenue
  • BDSX $65,562,000.00
  • EDIT $61,759,000.00
  • Revenue This Year
  • BDSX $46.97
  • EDIT N/A
  • Revenue Next Year
  • BDSX $30.43
  • EDIT N/A
  • P/E Ratio
  • BDSX N/A
  • EDIT N/A
  • Revenue Growth
  • BDSX 48.92
  • EDIT 150.95
  • 52 Week Low
  • BDSX $1.11
  • EDIT $1.28
  • 52 Week High
  • BDSX $2.21
  • EDIT $11.58
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 48.94
  • EDIT 24.88
  • Support Level
  • BDSX $1.24
  • EDIT $1.28
  • Resistance Level
  • BDSX $1.43
  • EDIT $2.37
  • Average True Range (ATR)
  • BDSX 0.10
  • EDIT 0.18
  • MACD
  • BDSX 0.01
  • EDIT -0.04
  • Stochastic Oscillator
  • BDSX 64.44
  • EDIT 6.45

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: